Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim and Horizon announce oncology alliance

Boehringer Ingelheim and Horizon announce oncology alliance

17th January 2013

Boehringer Ingelheim has signed an oncology-focused research service collaboration agreement with Horizon Discovery, a provider of research tools for the development of personalised medicines.

Under the terms of the deal, Boehringer Ingelheim will take advantage of Horizon's Discovery Toolbox for research projects and profiling of compounds at the hit-to-lead, lead optimisation and pre-clinical stages, in order to assess their potential anti-cancer properties.

Horizon will evaluate compounds across a broad panel of X-MAN isogenic models and selected 2D/3D phenotypic assays, as well as providing access to its custom cell line generation services to support the research.

Kam Dhaliwal, vice-president of sales at Horizon, said: "We are delighted that Boehringer Ingelheim has selected Horizon as a partner for its drug discovery programs, in recognition of the value our X-MAN cell lines and drug discovery services can add."

This comes after Boehringer Ingelheim and Apexigen signed a manufacturing agreement for process development and early-stage clinical supply last month.ADNFCR-8000103-ID-801523790-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.